{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:02:46Z","timestamp":1761541366177,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.brachy.2016.12.004","type":"journal-article","created":{"date-parts":[[2017,1,28]],"date-time":"2017-01-28T08:16:17Z","timestamp":1485591377000},"page":"348-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prostate-specific antigen density is predictive of outcome in suboptimal prostate seed brachytherapy"],"prefix":"10.1016","volume":"16","author":[{"given":"David","family":"Benzaquen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guila","family":"Delouya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"M\u00e9nard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maroie","family":"Barkati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5267-3213","authenticated-orcid":false,"given":"Daniel","family":"Taussky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2016.12.004_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00066-014-0762-6","article-title":"Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer: an interim analysis of 312 cases","volume":"191","author":"Badakhshi","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.brachy.2016.12.004_bib2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5489\/cuaj.1482","article-title":"Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: a systematic review","volume":"7","author":"Rodrigues","year":"2013","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.brachy.2016.12.004_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijrobp.2006.08.056","article-title":"Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation","volume":"67","author":"Zelefsky","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2016.12.004_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/01.ju.0000152558.63996.29","article-title":"Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer","volume":"173","author":"Stone","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.urolonc.2014.12.011","article-title":"What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series","volume":"33","author":"Gandaglia","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.brachy.2016.12.004_bib6","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.juro.2013.09.034","article-title":"Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer","volume":"191","author":"Vellekoop","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib7","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1016\/j.ijrobp.2011.02.037","article-title":"Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis","volume":"81","author":"Zilli","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2016.12.004_bib8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.eururo.2012.01.050","article-title":"Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades","volume":"61","author":"Epstein","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib9","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.juro.2014.09.094","article-title":"Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer","volume":"193","author":"Welty","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.juro.2010.01.001","article-title":"Risk stratification of men choosing surveillance for low risk prostate cancer","volume":"183","author":"Tseng","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.eururo.2014.10.010","article-title":"Active surveillance for prostate cancer: a systematic review of clinicopathologic variables and biomarkers for risk stratification","volume":"67","author":"Loeb","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2012.11.005","article-title":"Active surveillance for low-risk prostate cancer worldwide: the PRIAS study","volume":"63","author":"Bul","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib13","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5489\/cuaj.329","article-title":"PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer","volume":"6","author":"Sfoungaristos","year":"2012","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.brachy.2016.12.004_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/pcan.2010.36","article-title":"Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance","volume":"14","author":"Kotb","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.brachy.2016.12.004_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4103\/0974-7796.152118","article-title":"Prostate-specific antigen density as a parameter for the prediction of positive lymph nodes at radical prostatectomy","volume":"7","author":"Yiakoumos","year":"2015","journal-title":"Urol Ann"},{"key":"10.1016\/j.brachy.2016.12.004_bib16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bju.12131","article-title":"Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density","volume":"113","author":"Umbehr","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.brachy.2016.12.004_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.juro.2010.09.115","article-title":"Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance","volume":"185","author":"San Francisco","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib18","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.ejca.2007.09.022","article-title":"Prostate volume and adverse prostate cancer features: fact not artifact","volume":"43","author":"Briganti","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.brachy.2016.12.004_bib19","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/JCO.2005.05.525","article-title":"Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study","volume":"23","author":"Freedland","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2016.12.004_bib20","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.ijrobp.2010.01.023","article-title":"Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size","volume":"79","author":"Nguyen","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2016.12.004_bib21","first-page":"64","article-title":"Brachytherapy in patients with small prostate glands","volume":"6","author":"Loblaw","year":"2000","journal-title":"Tech Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib22","first-page":"233","article-title":"Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation","volume":"7","author":"Merrick","year":"2001","journal-title":"Tech Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0360-3016(03)00783-1","article-title":"Influence of prostate volume on dosimetry results in real-time 125I seed implantation","volume":"58","author":"McNeely","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2016.12.004_bib24","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ijrobp.2009.04.014","article-title":"Permanent prostate brachytherapy in prostate glands <20 cm(3)","volume":"76","author":"Mayadev","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2016.12.004_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.brachy.2012.07.001","article-title":"Impact of small prostate size on postimplant prostate dosimetry: analysis of a large community database","volume":"12","author":"Taira","year":"2013","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2016.12.004_bib26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0022-5347(17)40079-6","article-title":"Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia","volume":"143","author":"Partin","year":"1990","journal-title":"J Urol"},{"key":"10.1016\/j.brachy.2016.12.004_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brachy.2013.11.010","article-title":"Rebuttal to Drs Stone and Stock","volume":"13","author":"Spadinger","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2016.12.004_bib28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1538-4721(02)00014-4","article-title":"Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy","volume":"1","author":"Crook","year":"2002","journal-title":"Brachytherapy"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472116306456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472116306456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:11:01Z","timestamp":1761531061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472116306456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S1538472116306456"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2016.12.004","relation":{},"ISSN":["1538-4721"],"issn-type":[{"type":"print","value":"1538-4721"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate-specific antigen density is predictive of outcome in suboptimal prostate seed brachytherapy","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}